Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells

被引:76
|
作者
Vassena, R. [1 ]
Heindryckx, B. [2 ]
Peco, R. [3 ]
Pennings, G. [4 ]
Raya, A. [3 ,5 ,6 ]
Sermon, K. [7 ]
Veiga, A. [3 ,8 ]
机构
[1] Clin EUGIN, Travessera Corts 322, Barcelona 08029, Spain
[2] Ghent Univ Hosp, Dept Reprod Med, Ghent Fertil & Stem Cell Team G FaST, Ghent, Belgium
[3] Ctr Regenerat Med Barcelona CMRB, Barcelona 08003, Spain
[4] Univ Ghent, Fac Arts & Philosophy, Bioeth Inst Ghent BIG, Ghent, Belgium
[5] ICREA, Barcelona 08010, Spain
[6] Ctr Networked Biomed Res Bioengn Biomat & Nanomed, Madrid 28029, Spain
[7] Vrije Univ Brussel, Res Grp Reprod & Genet, Brussels, Belgium
[8] Hosp Univ Quiron Dexeus, Reprod Med Serv, Barcelona, Spain
关键词
human embryo; CRISPR; Cas9; genome editing; germline modification; stem cells; oocyte; sperm; IN-VIVO; HOMOLOGOUS RECOMBINATION; DIRECT-INJECTION; GENE-EXPRESSION; DNA-SEQUENCES; MOUSE MODEL; CAS SYSTEM; KNOCK-IN; RNA; CRISPR-CAS9;
D O I
10.1093/humupd/dmw005
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
With the recent development of CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 genome editing technology, the possibility to genetically manipulate the human germline (gametes and embryos) has become a distinct technical possibility. Although many technical challenges still need to be overcome in order to achieve adequate efficiency and precision of the technology in human embryos, the path leading to genome editing has never been simpler, more affordable, and widespread. In this narrative review we seek to understand the possible impact of CRISR/Cas9 technology on human reproduction from the technical and ethical point of view, and suggest a course of action for the scientific community. This non-systematic review was carried out using Medline articles in English, as well as technical documents from the Human Fertilisation and Embryology Authority and reports in the media. The technical possibilities of the CRISPR/Cas9 technology with regard to human reproduction are analysed based on results obtained in model systems such as large animals and laboratory rodents. Further, the possibility of CRISPR/Cas9 use in the context of human reproduction, to modify embryos, germline cells, and pluripotent stem cells is reviewed based on the authors' expert opinion. Finally, the possible uses and consequences of CRISPR/cas9 gene editing in reproduction are analysed from the ethical point of view. We identify critical technical and ethical issues that should deter from employing CRISPR/Cas9 based technologies in human reproduction until they are clarified. Overcoming the numerous technical limitations currently associated with CRISPR/Cas9 mediated editing of the human germline will depend on intensive research that needs to be transparent and widely disseminated. Rather than a call to a generalized moratorium, or banning, of this type of research, efforts should be placed on establishing an open, international, collaborative and regulated research framework. Equally important, a societal discussion on the risks, benefits, and preferred applications of the new technology, including all relevant stakeholders, is urgently needed and should be promoted, and ultimately guide research priorities in this area.
引用
收藏
页码:411 / 419
页数:9
相关论文
共 50 条
  • [41] p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells
    Ihry, Robert J.
    Worringer, Kathleen A.
    Salick, Max R.
    Frias, Elizabeth
    Ho, Daniel
    Theriault, Kraig
    Kommineni, Sravya
    Chen, Julie
    Sondey, Marie
    Ye, Chaoyang
    Randhawa, Ranjit
    Kulkarni, Tripti
    Yang, Zinger
    McAllister, Gregory
    Russ, Carsten
    Reece-Hoyes, John
    Forrester, William
    Hoffman, Gregory R.
    Dolmetsch, Ricardo
    Kaykas, Ajamete
    NATURE MEDICINE, 2018, 24 (07) : 939 - +
  • [42] Optimization of Genome Engineering Approaches with the CRISPR/Cas9 System
    Li, Kai
    Wang, Gang
    Andersen, Troels
    Zhou, Pingzhu
    Pu, William T.
    PLOS ONE, 2014, 9 (08):
  • [43] CRISPR/Cas9 Immune System as a Tool for Genome Engineering
    Magdalena Hryhorowicz
    Daniel Lipiński
    Joanna Zeyland
    Ryszard Słomski
    Archivum Immunologiae et Therapiae Experimentalis, 2017, 65 : 233 - 240
  • [44] CRISPR/Cas9 Immune System as a Tool for Genome Engineering
    Hryhorowicz, Magdalena
    Lipianki, Daniel
    Zeyland, Joanna
    Slomski, Ryszard
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2017, 65 (03) : 233 - 240
  • [45] CRISPR–Cas9 System for Genome Engineering of Photosynthetic Microalgae
    Vikas Kumar Patel
    Niraja Soni
    Venkatesh Prasad
    Ajit Sapre
    Santanu Dasgupta
    Bhaskar Bhadra
    Molecular Biotechnology, 2019, 61 : 541 - 561
  • [46] The Potential of the Combination of CRISPR/Cas9 and Pluripotent Stem Cells to Provide Human Organs from Chimaeric Pigs
    Feng, Wanyou
    Dai, Yifan
    Mou, Lisha
    Cooper, David K. C.
    Shi, Deshun
    Cai, Zhiming
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (03): : 6545 - 6556
  • [47] Highly parallel genome variant engineering with CRISPR–Cas9
    Meru J. Sadhu
    Joshua S. Bloom
    Laura Day
    Jake J. Siegel
    Sriram Kosuri
    Leonid Kruglyak
    Nature Genetics, 2018, 50 : 510 - 514
  • [48] CRISPR/Cas9 technology: from cells to mice to stem cell therapy
    Te Riele, H.
    Harmsen, T.
    Van de Vrugt, H.
    Riepsaame, J.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S1 - S1
  • [49] Engineering Cas9 for human genome editing
    Slaymaker, Ian M.
    Gaudelli, Nicole M.
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2021, 69 : 86 - 98
  • [50] Generation of an RNF1-deficient human pluripotent stem cell line using CRISPR/Cas9 technology
    Zhang, Di
    Zhou, Min
    Zhang, Yanqi
    Shan, Yongli
    Pan, Guangjin
    STEM CELL RESEARCH, 2022, 62